Sernova logo

Sernova Stock

StockStock
ISIN: CA81732W1041
Ticker: SVA
CA81732W1041
SVA

Price

Frequently asked questions

What is Sernova's market capitalization?

The market capitalization of Sernova is $56.05M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Sernova?

Sernova's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.092. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Sernova's stock?

Currently, 6 analysts cover Sernova's stock, with a consensus target price of $2.522. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Sernova?

Sernova's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$27.47M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Sernova?

Sernova has a free cash flow of -$18.88M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Sernova's stock?

The 5-year beta for Sernova is 1.31. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

What is the free float of Sernova's shares?

The free float of Sernova is 285.85M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$56.05M

5Y beta

 
1.31

EPS (TTM)

 
-$0.092

Free Float

 
285.85M

EBITDA (TTM)

 
-$27.47M

Free Cashflow (TTM)

 
-$18.88M

Pricing

1D span
$0.165$0.176
52W span
$0.146$0.566

Analyst Ratings

The price target is $2.522 and the stock is covered by 6 analysts.

Buy

5

Hold

1

Sell

0

Information

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

Biotechnology & Drugs

Health Care

Identifier

ISIN

CA81732W1041

Primary Ticker

SVA

Knockouts

Join the conversation